

# FINAL - October 14 2016

## MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium

Atlanta, Georgia 30329

October 19-20, 2016

<u>AGENDA ITEM</u>	<u>PURPOSE</u>	<u>PRESIDER/PRESENTER(s)</u>
<b>Wednesday, October 19</b>		
<b>8:00 Welcome &amp; Introductions</b>		Dr. Nancy Bennett (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary; CDC)
<b>8:30 Hepatitis Vaccines</b>		
Introduction	Information & Discussion	Dr. José Romero (ACIP, WG Member)
Updated hepatitis B vaccine recommendations	<u>Vote</u>	Dr. Sarah Schillie (CDC/NCHSTP)
VFC resolution	<u>VFC Vote</u>	Dr. Jeanne Santoli (CDC/NCIRD)
<b>9:30 Pertussis Vaccines</b>		
Introduction	Information & Discussion	Dr. Laura Riley (ACIP, WG Member)
Guidance on timing of Tdap administration during pregnancy		Dr. Jennifer Liang (CDC/NCIRD)
Public comment		
Updated ACIP statement for pertussis, tetanus and diphtheria vaccines	<u>Vote</u>	Dr. Jennifer Liang (CDC/NCIRD)
<b>10:40 Break</b>		
<b>11:10 Human Papillomavirus (HPV) Vaccines</b>		
Introduction	Information & Discussion	Dr. Allison Kempe (ACIP, WG Chair)
Review of evidence for 2-dose vaccination schedule		Dr. Lauri Markowitz (CDC/NCIRD)
Proposed recommendations for 2-dose HPV vaccination		Dr. Elissa Meites (CDC/NCIRD)
Public comment		
Recommendation vote	<u>Vote</u>	Dr. Elissa Meites (CDC/NCIRD)
VFC resolution	<u>VFC Vote</u>	Dr. Jeanne Santoli (CDC/NCIRD)
<b>12:30 Lunch</b>		
<b>1:45 Meningococcal Vaccines</b>		
Introduction		Dr. David Stephens (ACIP, WG Chair)
Impact of MenB-FHbp (Trumenba) on meningococcal carriage		Dr. Heidi Soeters (CDC/NCIRD)
Immunogenicity studies of two MenB vaccines in adults	Information & Discussion	Dr. Dan Granoff (Children's Hospital Oakland Research Institute)
MenB-FHbp update		Dr. Laura York (Pfizer)
Considerations for use of 2- and 3-dose schedules of MenB-FHbp		Ms. Jessica MacNeil (CDC/NCIRD)
Public comment		
Recommendation vote	<u>Vote</u>	Ms. Jessica MacNeil (CDC/NCIRD)
VFC resolution	<u>VFC Vote</u>	Dr. Jeanne Santoli (CDC/NCIRD)
<b>3:30 Break</b>		
<b>4:00 Herpes Zoster Vaccines</b>		
Introduction		Dr. Edward Belongia (ACIP, WG Chair)
Herpes zoster background	Information & Discussion	Dr. Kathleen Dooling (CDC/NCIRD)
Herpes zoster vaccine update: Herpes Zoster Subunit (HZ/su) Vaccine		Dr. Romulo Colindres (GlaxoSmithKline)
<b>5:15 Yellow Fever Vaccine</b>		
Update on vaccine supply	Information	Dr. Mark Gershman (CDC/NCEZID)
<b>5:30 Public Comment</b>		
<b>5:45 Adjourn</b>		

## FINAL - October 14 2016

### Thursday, October 20

<b>8:00 Update: Zika Virus</b>	Information	Ms. Stacey Martin (CDC/NCEZID)
<b>8:15 Agency Updates</b> CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO	Information	Dr. Nancy Messonnier (CDC/NCIRD); CDC and Ex <i>Officio</i> Members
<b>8:30 Child/adolescent Immunization Schedule</b> Introduction  Child/adolescent immunization schedule	Information & Discussion  <b><u>Vote</u></b>	Dr. José Romero (ACIP, WG Chair)  Dr. Candice Robinson (CDC/NCIRD)
<b>9:30 Adult Immunization Schedule</b> Introduction  Adult immunization schedule	Information & Discussion  <b><u>Vote</u></b>	Dr. Laura Riley (ACIP, WG Chair)  Dr. David Kim (CDC/NCIRD)
<b>10:15</b>	<b><i>Break</i></b>	
<b>10:30 Pneumococcal Vaccine</b> Introduction Direct and indirect impact of PCV13 use on invasive disease among adults and children in the US Changes in invasive disease burden among adults with and without indications for PCV13 use Outline of research agenda to inform potential policy change in 2018 for PCV13 use among adults	Information & Discussion	Dr. Allison Kempe (ACIP, WG Member) Ms. Tamara Pilishvili (CDC/NCIRD)  Dr. Sana Ahmed (CDC/NCIRD)  Ms. Tamara Pilishvili (CDC/NCIRD)
<b>11:30 Influenza</b> Introduction Epidemiology/surveillance update Afluria quadrivalent influenza vaccine	Information & Discussion	Dr. Chip Walter (ACIP, WG Chair) Ms. Lynette Brammer (CDC/NCIRD) Seqirus - Dr. Gregg Sylvester
<b>12:30</b>	<b><i>Lunch</i></b>	
<b>1:30 Respiratory Syncytial Virus (RSV) Vaccine</b> Introduction Burden of disease in older adults  Update on Novavax RSV vaccine development programs	Information & Discussion	Dr. Robert Atmar (ACIP, WG Chair) Dr. Ann Falsey (University of Rochester)  Novavax - Dr. Jeffrey Stoddard, Vice President, Medical Affairs
<b>2:45 Evidence Based Recommendations</b>	Information & Discussion	Dr. Wendy Carr (CDC/NCIRD)
<b>3:00 Vaccine Supply</b>	Information	Dr. Jeanne Santoli (CDC/NCIRD)
<b>3:10 Public Comment</b>		
<b>3:30 Adjourn</b>		

#### ***Acronyms***

CDC	Centers for Disease Control & Prevention
CMS	Centers for Medicare and Medicaid Services
DoD	Department of Defense
DVA	Department of Veterans Affairs
Tdap	Tetanus, Diphtheria, Acellular Pertussis Vaccine
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIH	National Institutes of Health
NVPO	National Vaccine Program Office
VFC	Vaccines for Children
WG	Work Group